Hodgkin’s disease is highly curable today. For early stages (stages I, II, and IIIA), radiotherapy is the treatment of choice. Although this treatment has been successful for more than three decades, no definite recommendations can be made as yet regarding the dose requirements because considerable controversy still exists on this subject. Here we review the literature in terms of dose-response data for Hodgkin’s disease. This review is intended to serve as a guide for a practicing clinician who is deciding on dose selection for the radiotherapy of Hodgkin’s disease. There is a trend toward higher in-field disease control at lower doses of megavoltage radiotherapy. There is also a suggestion that, currently, more than the necessary doses are being used for in-field disease control. Results should be reported in terms of disease burden so that dose prescriptions can be tailored to the malignant-cell burden in the future.